The molecular landscape of squamous cell carcinoma of the head and the neck (SCCHN) has been characterized and actionable or targetable genomic alterations have been identified. However, targeted therapies have very limited activity in unselected SCCHN, and the current treatment strategy is still based on tumor location and disease stage and not on tumor biology. Trying to select upfront the patients who will benefit from a specific treatment might be a way to improve patients' outcome. With the objective of optimizing the activity of targeted therapies and immunotherapy, we have designed an umbrella biomarker-driven study dedicated to recurrent and/or metastatic SCCHN patients (EORTC-1559-HNCG, NCT03088059). In this article, we review not only the different trial designs for biomarker-driven studies with their respective advantages and opportunities but also the potential pitfalls that led to the design of the EORTC-1559-HNCG protocol. We also discuss the scientific and logistic challenges of biomarker-driven trials.

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach / R. Galot, C. Le Tourneau, J. Guigay, L. Licitra, I. Tinhofer, A. Kong, C. Caballero, C. Fortpied, J. Bogaerts, A. Govaerts, D. Staelens, T. Raveloarivahy, L. Rodegher, J. Laes, E. Saada-Bouzid, J. Machiels. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 29:12(2018 Dec 01), pp. 2313-2327. [10.1093/annonc/mdy452]

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach

L. Licitra;
2018

Abstract

The molecular landscape of squamous cell carcinoma of the head and the neck (SCCHN) has been characterized and actionable or targetable genomic alterations have been identified. However, targeted therapies have very limited activity in unselected SCCHN, and the current treatment strategy is still based on tumor location and disease stage and not on tumor biology. Trying to select upfront the patients who will benefit from a specific treatment might be a way to improve patients' outcome. With the objective of optimizing the activity of targeted therapies and immunotherapy, we have designed an umbrella biomarker-driven study dedicated to recurrent and/or metastatic SCCHN patients (EORTC-1559-HNCG, NCT03088059). In this article, we review not only the different trial designs for biomarker-driven studies with their respective advantages and opportunities but also the potential pitfalls that led to the design of the EORTC-1559-HNCG protocol. We also discuss the scientific and logistic challenges of biomarker-driven trials.
Settore MED/06 - Oncologia Medica
1-dic-2018
11-ott-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
pmid 30307465.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 836.73 kB
Formato Adobe PDF
836.73 kB Adobe PDF Visualizza/Apri
mdy452.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 359.93 kB
Formato Adobe PDF
359.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/603472
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 41
social impact